Published in Liver Int on November 01, 2012
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology (2006) 1.95
Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol (2011) 1.79
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med (2006) 1.67
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 1.60
Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology (2002) 1.50
The diversity of O-linked glycans expressed during Drosophila melanogaster development reflects stage- and tissue-specific requirements for cell signaling. J Biol Chem (2008) 1.47
Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology (2003) 1.42
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. PLoS Genet (2012) 1.27
The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol (2007) 1.25
Cirrhotic cardiomyopathy. Semin Liver Dis (2008) 1.21
Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol (2006) 1.19
Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol (2010) 1.18
Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int (2008) 1.13
Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int (2007) 1.11
Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol (2005) 1.10
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A (2013) 1.06
Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol (2006) 1.06
Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol (2011) 1.05
Cirrhotic cardiomyopathy. Orphanet J Rare Dis (2007) 1.03
Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol (2007) 1.02
Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol (2005) 1.02
How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int (2013) 1.01
Prediction of cardiac complications after liver transplantation. Transplantation (2009) 1.00
Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol (2005) 0.99
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Amiodarone hepatotoxicity. Curr Vasc Pharmacol (2008) 0.98
The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol (2002) 0.97
Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol (2009) 0.97
Management of hepatitis C virus genotype 4. J Gastroenterol Hepatol (2004) 0.97
Cirrhotic cardiomyopathy. Gastroenterol Clin Biol (2002) 0.95
Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) (2002) 0.93
Emergency management of bleeding esophageal varices: drugs, bands or sleep? Can J Gastroenterol (2006) 0.92
Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology (2002) 0.90
Portal vein thrombosis: should anticoagulation be used? Curr Gastroenterol Rep (2013) 0.89
Cirrhotic cardiomyopathy. Ann Hepatol (2006) 0.88
Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus. Liver Int (2007) 0.88
Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. Cancer Discov (2013) 0.87
Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int (2008) 0.85
Cheating in scientific publishing: the scourge must stop! Liver Int (2008) 0.85
Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology (2003) 0.85
Concurrence of primary biliary cirrhosis and antiphospholipid antibody syndrome. Am J Gastroenterol (2004) 0.84
B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol (2013) 0.84
Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis (2013) 0.84
Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol (2013) 0.83
Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. Inflamm Bowel Dis (2007) 0.83
Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol (2008) 0.82
What happens to cirrhotic cardiomyopathy after liver transplantation? Hepatology (2005) 0.81
Altered mesenteric venous capacitance and volume pooling in cirrhotic rats are mediated by nitric oxide. Am J Physiol Gastrointest Liver Physiol (2008) 0.80
Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats. J Hepatol (2011) 0.79
Pay now or pay (more) later: tracking the costs of hepatitis C infection. Can J Gastroenterol (2010) 0.79
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci (2014) 0.79
Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol (2010) 0.78
Acute-on-chronic liver failure: the heart and systemic hemodynamics. Curr Opin Crit Care (2011) 0.78
Hepatic nodular regenerative hyperplasia in a patient with advanced carcinoid tumor. Eur J Gastroenterol Hepatol (2009) 0.77
The spleen is a player in portal hypertension. Exp Physiol (2012) 0.77
Role of ICAM-1 in chronic hepatic allograft rejection in the rat. Am J Physiol Gastrointest Liver Physiol (2002) 0.77
Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change. Can J Gastroenterol (2011) 0.76
Acute coinfection with hepatitis B and hepatitis C viruses. Can J Gastroenterol (2005) 0.76
Vasopressin antagonists and dilutional hyponatremia. Can J Gastroenterol (2004) 0.76
Hemodynamics in the immediate post-transplantation period in alcoholic and viral cirrhosis. World J Gastroenterol (2010) 0.76
Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis. Expert Opin Pharmacother (2013) 0.76
High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. Clin Gastroenterol Hepatol (2012) 0.75
Impact of pharmaceutical industry versus university sponsorship on survey response: a randomized trial among Canadian hepatitis C care providers. Can J Gastroenterol (2007) 0.75
Hepatitis C, insulin resistance and fatty liver: bad things come in threes. Can J Gastroenterol (2012) 0.75
Chronic hepatitis C in Western Canada: a survey of practice patterns among gastroenterologists in Alberta and British Columbia. Can J Gastroenterol Hepatol (2013) 0.75
PPARα activation in portal hypertension. Hepatology (2012) 0.75
Liver transplantation for alcoholic liver disease: a devilish dilemma. Can J Gastroenterol (2013) 0.75
Predicting cardiovascular complications after liver transplantation: 007 to the rescue? Liver Transpl (2011) 0.75
Acute management and secondary prophylaxis of esophageal variceal bleeding: a western Canadian survey. Can J Gastroenterol (2006) 0.75
Chronic hepatitis B--who should be treated? MedGenMed (2006) 0.75
Correction: Hepatitis B Virus (HBV) Variants in Untreated and Tenofovir Treated Chronic Hepatitis B (CHB) Patients During Pregnancy and Post-Partum Follow-up. PLoS One (2015) 0.75
Hepatitis C virus infection in Canada's First Nations people: a growing problem. Can J Gastroenterol (2013) 0.75
Protective effects of erythropoietin on cirrhotic cardiomyopathy in rats. Dig Liver Dis (2012) 0.75
Is pre-treatment liver biopsy necessary for all hepatitis C genotypes? Ann Hepatol (2011) 0.75
Change in lipid profile and impairment of endothelium-dependent relaxation of blood vessels in rats after bile duct ligation. Life Sci (2003) 0.75
The power of one and saving private Braillon. Liver Int (2012) 0.75
Identifying HCV genotype 1 patients at risk of relapse. Eur J Gastroenterol Hepatol (2010) 0.75
'Foie cardiaque': a new name for an old syndrome? Liver Int (2008) 0.75
Treatment of HBeAg-positive patients with nucleos/tide analogues. Liver Int (2009) 0.75
Gens Una Sumus--still. Liver Int (2013) 0.75
Pleasing and displeasing things. Liver Int (2010) 0.75
Authorship: pride and proliferation. Liver Int (2009) 0.75
How to write a paper: an editor's tips. Liver Int (2008) 0.75
Editor's report: reflections on the first year. Liver Int (2008) 0.75
Health and socioeconomic status differences among antibody hepatitis C positive and negative transfusion recipients, 1986-1990. Can J Public Health (2003) 0.75